RDHL Stock Summary and Trading Ideas (Redhill Biopharma Ltd. - American Depositary Shares | NASDAQ:RDHL)

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.

Redhill Biopharma Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol RDHL.

As of April 18, 2024, RDHL stock price climbed to $0.42 with 633,053 million shares trading.

RDHL has a beta of -0.16, meaning it tends to be less sensitive to market movements. RDHL has a correlation of 0.00 to the broad based SPY ETF.

RDHL has a market cap of $13.41 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, RDHL stock traded as high as $447.20 and as low as $.26.

RDHL has underperformed the market in the last year with a price return of -86.9% while the SPY ETF gained +22.3%. RDHL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -59.5% and -20.6%, respectively, while the SPY returned +6.1% and -3.8%, respectively.

RDHL support price is $.36 and resistance is $.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RDHL stock will trade within this expected range on the day.